No Data
Will Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?
Buy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline Progress
B.Riley Financial Maintains Ovid Therapeutics(OVID.US) With Buy Rating, Cuts Target Price to $3
Oppenheimer Maintains Ovid Therapeutics(OVID.US) With Hold Rating
Oppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)
Ovid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate In Animal Eyes in Contrast With Vigabatrin